Step 1 topics → Neurology and Special Senses → Adult CNS Tumors

Adult CNS Tumors

Adult CNS tumors are a high-yield neuropathology topic that rewards students who know the defining histologic features and molecular markers for each tumor type. USMLE Step 1 tests this at multiple levels: pure recall (what cells does meningioma arise from?), histology recognition (what do fried egg cells tell you?), and clinical-pathologic correlation (patient with bilateral hearing loss and a genetic syndrome — which gene?). You need to know not just what each tumor looks like, but where it sits, who gets it, and what makes it behave the way it does.

The tricky part is that these tumors blur together under pressure. GBM, meningioma, schwannoma, and oligodendroglioma each have a distinct identity, but students routinely mix up the histologic buzzwords, confuse NF1 with NF2, and misremember which molecular markers actually define a diagnosis. USMLE Step 1 exploits exactly these confusions — especially the NF1/NF2 swap and the incomplete understanding of what makes oligodendroglioma a distinct WHO entity.

Approach this topic by anchoring each tumor to one non-negotiable fact: GBM has pseudopalisading necrosis and microvascular proliferation; meningioma comes from arachnoid cap cells (not dura); schwannoma stains S-100 and bilateral acoustic = NF2; oligodendroglioma requires both IDH mutation AND 1p/19q co-deletion. Once those anchors are solid, the clinical vignettes become much more manageable.

From real student decks
95%have cards covering this topic
84%have mature cards
2median lapses in 14 days

Well-covered in most decks — the challenge is retention, not exposure.

Common misconceptions

Common mistake
Gap: Unaware that pseudopalisading necrosis and microvascular proliferation are the defining histologic features of GBM
Glioblastoma (WHO grade IV) is characterized histologically by pseudopalisading necrosis and microvascular proliferation, which distinguish it from lower-grade gliomas.
Students often know GBM is 'bad' but can't name the specific histologic features that make it WHO grade IV. Pseudopalisading necrosis refers to tumor cell nuclei lining up around central zones of necrosis — this isn't just flavor; it's the diagnostic marker on biopsy. Microvascular proliferation (glomeruloid tufts of blood vessels) is the second required feature. If you see both in a vignette describing a brain biopsy in an older adult, that's GBM until proven otherwise.
Common mistake
Wrong: Meningiomas arise from the dura mater.
Right: Meningiomas arise from arachnoid cap cells of the meninges, not from the dura itself.
Meningiomas feel like they should come from the dura because they sit on the inner surface of the skull and attach to dural folds — but the cell of origin is the arachnoid cap cell (also called meningothelial cell), which is part of the arachnoid layer. This matters because it explains why meningiomas are external to the brain parenchyma, why they're often resectable, and why they can show whorling patterns and psammoma bodies on histology that reflect their arachnoid cell heritage.
Common mistake
Wrong: Students associate bilateral acoustic schwannomas with NF1.
Right: Bilateral vestibular (acoustic) schwannomas are pathognomonic for NF2, not NF1; NF1 is associated with neurofibromas and optic gliomas.
NF1 and NF2 are completely different genetic diseases that happen to share a name prefix, and Step 1 tests this distinction aggressively. NF1 (chromosome 17, neurofibromin) gives you café-au-lait spots, neurofibromas, Lisch nodules, and optic gliomas. NF2 (chromosome 22, merlin) gives you bilateral vestibular schwannomas — full stop. If a vignette mentions bilateral hearing loss or bilateral CN VIII tumors, the answer is NF2, not NF1.
Common mistake
Wrong: IDH mutation alone defines oligodendroglioma and confers better prognosis.
Right: Oligodendroglioma is defined by both IDH mutation and 1p/19q co-deletion, which together confer better prognosis and chemosensitivity.
IDH mutations show up in many lower-grade gliomas, so IDH alone doesn't make something an oligodendroglioma. The defining molecular signature is IDH mutation PLUS 1p/19q co-deletion — both are required by the current WHO classification. The 1p/19q co-deletion is what predicts chemosensitivity (particularly to PCV or temozolomide) and drives the better prognosis. Knowing only IDH leaves out the half that makes oligodendroglioma clinically distinct.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. GBM: Know that glioblastoma is WHO grade IV, classically crosses the corpus callosum as a 'butterfly glioma,' and is defined histologically by pseudopalisading necrosis (tumor cells piling up around central necrotic zones) and microvascular proliferation — these two findings are what separates GBM from lower-grade gliomas.
  2. Meningioma: Know that meningiomas arise from arachnoid cap cells (not the dura), are the most common primary brain tumor in adults, are typically benign and slow-growing, can show psammoma bodies on histology, and often present with seizures or focal deficits depending on location.
  3. Schwannoma: Know that schwannomas arise from Schwann cells, stain positive for S-100, classically occur at the cerebellopontine angle (CN VIII = vestibular schwannoma / acoustic neuroma), and that BILATERAL vestibular schwannomas are pathognomonic for NF2 — not NF1.
  4. Oligodendroglioma: Know that the formal diagnosis requires BOTH an IDH mutation AND 1p/19q co-deletion — it is this combination that confers relatively better prognosis and chemosensitivity; IDH mutation alone is not sufficient to make the diagnosis or explain the favorable behavior.

Can you avoid these mistakes?

A 62-year-old man undergoes brain biopsy for a ring-enhancing lesion crossing the corpus callosum. Pathology shows tumor cells arranged around central necrotic foci and abnormal proliferating blood vessels. What is the diagnosis, and what are the two histologic features that clinch it?
A 45-year-old woman has a slowly growing extra-axial brain mass causing seizures. Biopsy shows whorling cells with calcified concentric structures. From what cell type does this tumor originate, and what are those calcifications called?
A 30-year-old man is found to have bilateral sensorineural hearing loss. Imaging shows masses at both cerebellopontine angles. Which genetic syndrome does this finding indicate, what chromosome is affected, and how does this differ from the other neurofibromatosis syndrome?
A frontal lobe tumor biopsy in a 35-year-old shows cells with round nuclei and clear cytoplasm (fried egg appearance). Molecular testing reveals an IDH mutation. Is this finding alone sufficient to diagnose oligodendroglioma and explain its better prognosis? What additional test result is required?

Related topics

Neural Tube Formation and Derivatives Neural Crest Derivatives Neural Tube Defects Other Developmental Malformations

See how your Anki deck covers this topic.

Upload your deck for a free audit →